Fagron N.V. : Unnecessary disappointment but too cheap to ignore
>Fagron lowering Wichita guide unnecessary negative surprise - Fagron’s 3Q22 trading update came in in line with css (<1% sales beat), with Latam coming in better than expected (9% beat), EMEA roughly in line (organically) and North America soft. The main surprise was the company lowering its December 2022 Wichita annualised run rate sales target to $95m ($115m including Boston), from $125m excluding Boston. We were negatively surprised by this guidance cut, especiall...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.